Back to search results

Long-term Safety Study of RP1, RP2, or RP3

This study is looking at the long-term safety of treatments called RP1, RP2, or RP3. It's for people who have already received at least one dose of one of these treatments in a previous study. The study aims to see if there are any delayed side effects, including new cancers, nerve problems, autoimmune disorders, blood problems, or infections related to the treatment, over a period of five years. This is an observational study, meaning you won't receive any new treatments. The study is currently unclear on its recruitment status and plans to include about 50 participants.

Study design
This is an observational study with no specified phase, planning to enroll 50 participants. It is not randomized or blinded.
What's involved
You will be contacted by telephone every three months for five years. These contacts may also occur in person, by video conference, or other technology.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for five years from enrollment to assess potential delayed risks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06887348

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

Recruiting
Not specifiedAges 18+Observational
Replimune, Inc.
~50 participants
Updated 2026-01-12 on ClinicalTrials.gov
What's tested:Observational study with no interventions

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluate the long-term safety of patients treated with an RPx product
Measured over Every 3 months (Q3M) (± 30 days) for 5 years from enrollment on this study to assess potential delayed risks
+2 more outcomes measured

Conditions

Melanoma
Metastatic Melanoma
Advanced Solid Tumor
Hepatocellular Carcinoma

Explore related trials

Hepatocellular CarcinomaMelanomaSolid Neoplasm

Where it's being run

2 sites across 2 states
California1
Queensland1

Who to contact

Clinical Trials at Replimune
[email protected]
1-781-222-9570
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Evaluate the long-term safety of patients treated with an RPx productEvery 3 months (Q3M) (± 30 days) for 5 years from enrollment on this study to assess potential delayed risks
  • Identify any delayed adverse event(s) related to treatment with an RPx productEvery 3 months (Q3M) (± 30 days) for 5 years from enrollment on this study to assess potential delayed risks
  • Identify systemic HSV-1 infection related to treatment with an RPx productEvery 3 months (Q3M) (± 30 days) for 5 years from enrollment on this study to assess potential delayed risks